Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-10-13

Target enrollment:

Participant gender:

This study is a proof-of-concept trial of vonafexor safety, its effects on kidney function in subjects with at risk of progression Alport syndrome.

PHASE2

Enyo Pharma